Literature DB >> 11012888

Diabetes mellitus increases endothelin-1 gene transcription in rat kidney.

G M Hargrove1, J Dufresne, C Whiteside, D A Muruve, N C Wong.   

Abstract

BACKGROUND: Mesangial cell hypertrophy and increased extracellular matrix (ECM) contribute to mesangial expansion in early progressive diabetic nephropathy. Previous studies suggest that the growth factor endothelin-1 (ET-1) is not only up-regulated in diabetes, but may mediate the effects of hyperglycemia on mesangial cell hypertrophy and ECM synthesis. In models of diabetes mellitus, the mechanisms underlying increased ET-1 peptide and mRNA remain unknown. Therefore, our purpose is to determine whether ET-1 gene activity increases in kidneys of streptozotocin (SZT)-treated rats.
METHODS: Male Sprague-Dawley rats were injected with either SZT or vehicle. Parameters including glucose, body weight, 24-hour urine volume, urinary protein, and urinary ET-1 excretion were recorded. All rats were sacrificed at 12 weeks postinjection. Prepro-ET-1 mRNA from whole kidneys was determined using both RNase protection and reverse transcription-polymerase chain reaction (RT-PCR). The abundance of ET-1 peptide in primary cultured mesangial cells was detected by indirect immunofluorescence following treatment with 5.6, 11.2, or 22.5 mmol/L D-glucose for 24 hours. Cellular ET-1 mRNA was measured using RT-PCR in control cells at time 0 and also following exposure to increasing concentrations of glucose for 24 hours. Rat mesangial cells were transfected with a luciferase reporter construct containing the rat ET-1 promoter (pET1. Luc), and relative ET-1 promoter activity was measured after a 24-hour exposure to 5.6 and 22.5 mmol/L of D- or L-glucose.
RESULTS: After 12 weeks of hyperglycemia, diabetic rats gained less weight (344 +/- 23.9 vs. 548.75 +/- 15.08 g), had increased urinary volume (158.6 +/- 24.32 vs. 8.38 +/- 1.56 mL/day), and had marked proteinuria (101.7 +/- 12.2 vs. 14.1 +/- 2.8 mg/day) compared with controls. Total urinary ET-1 peptide increased 26.4-fold in diabetic versus control rats (17.5083 +/- 5.405 vs. 0.6635 +/- 0.343 ng/day). ET-1 mRNA extracted from whole rat kidneys was increased 2.1-fold in diabetic versus control animals. Primary cultured rat mesangial cells demonstrated a significant increase in immunofluorescence labeling of ET-1 peptide and ET-1 mRNA in response to increasing concentrations of glucose. Furthermore, transfected mesangial cells exposed to 22.5 mmol/L D-glucose showed a 1.6-fold increase in ET-1 promoter activity relative to those treated with 5.6 mmol/L glucose.
CONCLUSION: Glucose increases ET-1 gene expression in the kidney of the SZT-treated rat model of diabetes mellitus. Furthermore, high glucose induces ET-1 expression in primary cultured rat mesangial cells and directly enhances ET-1 promoter activity. The greater relative increase in peptide compared with transcription suggests the potential participation of other mechanisms such as increased mRNA stability, protein stability, and/or enhanced translational efficiency.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11012888     DOI: 10.1046/j.1523-1755.2000.00315.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  19 in total

1.  Prevention of the progression of renal injury in diabetic rodent models with preexisting renal disease with chronic endothelin A receptor blockade.

Authors:  Denisha Spires; Bibek Poudel; Corbin A Shields; Alyssa Pennington; Brianca Fizer; Lateia Taylor; Kasi C McPherson; Denise C Cornelius; Jan M Williams
Journal:  Am J Physiol Renal Physiol       Date:  2018-05-30

2.  Blood glucose fluctuation accelerates renal injury involved to inhibit the AKT signaling pathway in diabetic rats.

Authors:  Changjiang Ying; Xiaoyan Zhou; Zhenzhen Chang; Hongwei Ling; Xingbo Cheng; Wei Li
Journal:  Endocrine       Date:  2016-02-09       Impact factor: 3.633

Review 3.  Cellular mechanisms and treatment of diabetes vascular complications converge on reactive oxygen species.

Authors:  Catharine I Whiteside
Journal:  Curr Hypertens Rep       Date:  2005-04       Impact factor: 5.369

4.  Enhanced vascular chymase-dependent conversion of endothelin in the diabetic kidney.

Authors:  Lisa M Harrison-Bernard; Lawrence de Garavilla; Benjamin J Bivona
Journal:  Ochsner J       Date:  2013

Review 5.  Nitric oxide in the normal kidney and in patients with diabetic nephropathy.

Authors:  Paolo Tessari
Journal:  J Nephrol       Date:  2014-09-13       Impact factor: 3.902

6.  Vascular Endothelial Growth Factor and Podocyte Protection in Chronic Hypoxia: Effects of Endothelin-A Receptor Antagonism.

Authors:  Taylor W Harvey; Jason E Engel; Alejandro R Chade
Journal:  Am J Nephrol       Date:  2016-03-02       Impact factor: 3.754

7.  Direct action of endothelin-1 on podocytes promotes diabetic glomerulosclerosis.

Authors:  Olivia Lenoir; Marine Milon; Anne Virsolvy; Carole Hénique; Alain Schmitt; Jean-Marc Massé; Yuri Kotelevtsev; Masashi Yanagisawa; David J Webb; Sylvain Richard; Pierre-Louis Tharaux
Journal:  J Am Soc Nephrol       Date:  2014-04-10       Impact factor: 10.121

Review 8.  Acute Kidney Injury and Progression of Diabetic Kidney Disease.

Authors:  Samuel Mon-Wei Yu; Joseph V Bonventre
Journal:  Adv Chronic Kidney Dis       Date:  2018-03       Impact factor: 3.620

9.  Microarray analysis of multiple candidate genes and associated plasma proteins for nephropathy secondary to type 2 diabetes among Chinese individuals.

Authors:  S C Lim; J J Liu; H Q Low; N G Morgenthaler; Y Li; L Y Yeoh; Y S Wu; S K Goh; C Y Chionh; S H Tan; Y C Kon; P C Soon; Y M Bee; T Subramaniam; C F Sum; K S Chia
Journal:  Diabetologia       Date:  2009-05-05       Impact factor: 10.122

10.  Diabetic Kidney Disease.

Authors:  Victoria E Bouhairie; Janet B McGill
Journal:  Mo Med       Date:  2016 Sep-Oct
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.